Amount of qualified individuals: CDEC mentioned the uncertainty in the number of patients with reasonably critical to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are categorized as getting mild or average condition might have a severe bleeding phenotype, https://hemgenix48089.blog-kids.com/36293967/the-basic-principles-of-hemgenix